D

Danaher

Makes tools for drug research and medical testing

Principal Manufacturing Process Engineer - Lifecycle Management

Full-Time
No salary listed
Senior
Bachelor's
Singapore
In PersonOn-site role in Singapore.
Manufacturing & Process EngineeringManufacturing Engineering

About the job

Requirements
  • A bachelor's degree in Mechatronics, Electrical, Electronics, Industrial, Production, or Mechanical Engineering, or a related engineering discipline.
  • At least 5 years of related experience in a Lean manufacturing or production environment, including at least 3 years in medical device manufacturing.
  • Knowledge of medical device quality and regulatory requirements, including ISO 13485 and Medical Device Single Audit Program requirements.
  • Experience with manufacturing process validation, jig and fixture design, Failure Mode and Effects Analysis, Design of Experiments, and structured root-cause problem solving.
  • Working knowledge of SAP and controlled manufacturing documentation, including process risk assessments, control plans, routings, inspection instructions, and production work instructions.
Responsibilities
  • Improve medical device manufacturing performance by monitoring First Pass Yield, process capability, productivity, Material Review Board trends, and recurring production issues, then implementing sustainable corrective and preventive actions.
  • Provide day-to-day process and product engineering support following new product design transfer, including troubleshooting, containment, root-cause analysis, complaint investigation, and resolution of manufacturing and product issues.
  • Plan, execute, document, and maintain qualification and validation of manufacturing processes, tools, fixtures, and equipment, including preventive maintenance requirements and process requalification.
  • Coordinate engineering changes and maintain production readiness across controlled documents, materials, tooling, training, SAP data, process risk assessments, control plans, routings, and work instructions.
  • Develop and sustain standard work and manufacturing playbooks using Lean and Danaher Business System tools, while supporting supplier qualification, first article testing, audits, inspection readiness, and compliance improvement activities.
Desired Qualifications
  • Experience supporting audits, inspection readiness, remediation activities, and Device History Record accuracy in a regulated manufacturing environment.
  • Experience leading complaint, warranty, corrective and preventive action, or supplier quality investigations through failure analysis and corrective-action implementation.
  • Experience delivering production training and deploying Lean or Danaher Business System standard work across assembly operations.

About the company

D

Danaher

View
Website

Danaher makes instruments, tests and laboratory supplies for drug developers, researchers and clinicians, spanning the path from biological research to clinical patient diagnosis. Its businesses include Cytiva for drug manufacturing, SCIEX for chemical analysis and Beckman Coulter for laboratory testing, linking specialized tools across healthcare workflows. Customers use its equipment to study cells, produce biological medicines and analyze patient samples; the group earns money by selling instruments, reagents, software and support services through its operating companies. Danaher was established in 1984 and is headquartered in Washington, DC.

Company Size

10,001+

Company Stage

IPO

Headquarters

Washington DC, District of Columbia

Founded

1984

Get referred to Danaher

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Danaher expands bedside testing: its June 2026 Masimo acquisition adds oxygen sensors and patient monitoring.
  • Careers span Danaher businesses: one HR manager moved through IDBS, Molecular Devices and SCIEX.
  • Danaher sales are recovering: July 2026 reporting showed second-quarter revenue rising 5.5% from a year earlier.

What critics are saying

  • Work revolves around targets: Danaher's Business System requires measurable goals and routine progress monitoring.
  • Danaher's respiratory test demand fluctuates: illness severity determines sales volumes outside management's control.
  • Spin-offs leave Danaher exposed: Veralto and Fortive separations retain tax indemnity risks.

What makes Danaher unique

  • Danaher standardizes improvement: its Business System applies shared methods across every operating company.
  • Danaher preserves business identities: its decentralized structure keeps acquired companies distinct within the group.
  • Repeat purchases anchor Danaher Diagnostics: 89% of segment sales come from consumables, services and equipment leases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Limited
  • Paid Vacation
  • Paid Holidays
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Stock Options

Growth & Insights and Company News

6 month growth

6%

1 year growth

5%

2 year growth

-4%
HR Trends
Oct 26th, 2026
Company's DEI policy made White men 'second-class' candidates, judge rules.

Company's DEI policy made White men 'second-class' candidates, judge rules. A group of White male current and former employees of Danaher Corp. may proceed with their lawsuit alleging that the company's diversity, equity and inclusion policies discriminated against them on the basis of race and sex, a federal judge held Friday. Plaintiffs in Critelli v. Danaher Corp. first claimed in a September 2025 complaint that the life sciences, diagnostics and biotechnology company required diverse interview slates. Namely, the company sought to achieve a benchmark of "50% underrepresented candidates interviewed," plaintiffs alleged, including women and people of color within that group. The challenged policies allegedly violated Title VII of the 1964 Civil Rights Act, Section 1981 of the 1866 Civil Rights Act and state laws. The plaintiffs' initial complaint incorporated age discrimination claims as well, but those claims were not included in an amended complaint filed in February. Judge Anne Leigh Gaylord Moe of the U.S. District Court for the Middle District of Florida partly denied Danaher's motion to dismiss, writing that four of the plaintiffs successfully showed that they were rejected in favor of less-qualified applications because of the company's DEI policy. Specifically, Moe noted the plaintiffs' allegations that Danaher loosened job requirements for underrepresented candidates, shortlisted those candidates for interviews and tied talent acquisition employees' performance evaluations and pay to meet DEI goals. "The Plaintiffs aren't entirely certain what Danaher means by 'people of color,' but whoever gets the benefit of that designation, it isn't white men," Moe said. "White men are effectively second-class candidates, even if they are more qualified." Danaher had argued, in part, that the plaintiffs were "merely speculating about why they were not given interviews and promotions" and that its goals were not equivalent to race- or sex-based quotas. The company also said that the plaintiffs failed to show that it knew about their race. Moe disagreed, stating that the latter argument "misses the forest for the trees" and that it would have been illogical to engineer diverse hiring slates without knowing candidates' demographics. Separately, the judge agreed to dismiss one plaintiff's race discrimination claim while refusing to dismiss his sex discrimination claim. The plaintiff in question showed that he had not been passed over for a less-qualified female candidate, for whom Danaher waived a residency requirement, but did not show that the position had been filled by someone of a different race. Moe dismissed another plaintiff's claims for failure to state a claim with leave to amend, noting that he did not allege that he was qualified for the positions to which he applied and did not allege that the positions were filled by candidates outside of his protected class. Discrimination lawsuits filed by majority-group plaintiffs, sometimes referred to as reverse discrimination lawsuits, have gained increasing prominence in the employment space in recent years. In a notable 2025 decision, the U.S. Supreme Court in Ames v. Ohio Dept. of Youth Services unanimously struck down federal appeals courts' elevated pleading requirements for such plaintiffs. Majority-group plaintiffs have particularly targeted DEI programs in their legal filings. Organizational DEI practices have been scrutinized by authorities including the U.S. Equal Employment Opportunity Commission; EEOC and the U.S. Department of Justice specifically named diverse hiring slates an unlawful practice in guidance issued last year. Such practices would feature in lawsuits including a high-profile one against Wells Fargo, where plaintiffs alleged the bank required diverse hiring slates and hired candidates who were not qualified for certain roles. Parties to the dispute agreed to settle for $85 million. Discrimination claims against other forms of DEI programming have met with mixed results for plaintiffs. For example, a Pennsylvania federal judge in August partly sided with a White former HR employee who alleged that she experienced racial hostility and retaliation on the job. And weeks earlier, the 7th U.S. Circuit Court of Appeals partly sided with a White employee who sued over an employer's requirement that she adopt an "equity mindset." Conversely, the 10th Circuit held that a White Colorado corrections officer failed to show that his employer's DEI training, which dealt with topics such as racial sensitivity and historical oppression of racial minorities, created a hostile work environment.

BetaKit
Oct 26th, 2026
DropGenie raises $5 million USD backed by BDC to speed up biological discovery.

DropGenie raises $5 million USD backed by BDC to speed up biological discovery. Montréal and Boston-based biotech startup aims to draw more data out of small samples. From a single drop of blood, you can find a whole world of biological information. One biotech startup is hoping that its miniaturized technology can make scientific research easier and more efficient, even when very little patient material is available. DropGenie, based in Montréal and Boston, is betting its approach can help the pharmaceutical industry develop more therapies. The company announced on Monday morning that it has brought in BDC Capital's Thrive Fund as a new investor for its seed-plus financing, bringing the total equity round to $5 million USD ($7 million CAD). Massachusetts-based Skeleton Key had led that financing, alongside Merck Global Health Innovation Fund and CQDM, with participation from Montréal's Real Ventures and Anges Québec. DropGenie hopes to make personalized medicines possible "by doing the somewhat unsexy work of creating... automation systems." Alison Hirukawa, DropGenie Founded in 2018, DropGenie began when CEO Alison Hirukawa met her co-founders, who were working on a digital microfluidics platform. The platform used electrical signals to manipulate very small amounts of liquid to accomplish typical lab tasks. Hirukawa, who was a postdoctoral fellow at McGill University's Goodman Cancer Research Centre, met Hugo Sinha, Philippe Vo, and Mathieu Husser (who is no longer with the company) through a McGill-associated research project; the team decided to combine their technology with synthetic biology techniques to try to speed up the research process. "A lot of work in the early stages of discovery is extremely artisanal," Hirukawa said in an interview with BetaKit. "You'd have a PhD student doing a lot of manual work, and you're extremely constrained by...material from a patient, which is very finite." The startup plans to use the funding to drive commercialization of its first product, which puts gene editing on a tiny chip. The advantage is that it uses up to 100 times fewer cells, as well as less reagent - often expensive chemicals necessary for experiments - than traditional tests. Since CRISPR gene-editing technology was first successfully applied in 2013, scientists have used it as a tool to test which genes are responsible for certain traits or diseases. When doing a genetic screening, sometimes researchers must use CRISPR to edit genes - according to the company, DropGenie's method requires 100 times less volume than existing methods. But how does DropGenie's tech do this? Hirukawa said it's all about scaling samples "down into a droplet." Instead of transporting small sample liquids into different lab machines to do an experiment, it all happens on a small chip with a tiny amount of liquid. "A lot of reagents and materials in that world are super bespoke or expensive," she said. "Bringing down the volume and the amount of input required completely changes the cost profile." That's an attractive proposition for its target customers, who are heavy hitters in the pharmaceutical industry. So far, DropGenie has formed partnerships with AbbVie, UCB Pharma, as well as life science instrument companies like Danaher and Sartorius. There's another way DropGenie's tech could prove valuable in the age of AI. Many companies are using AI models to enhance and speed up drug discovery, and for that, they need a lot of high-quality data. With its faster screening methods, DropGenie "generates the high-quality, human-relevant data those models need," BDC Thrive Fund managing director Mona Minhas said in a statement. DropGenie hopes to sell its automated lab workflows as a service with a commercial launch in the second quarter of next year. It also wants to ink more data partnerships and grow its 10-person team, split between offices in Montréal and Cambridge, Mass. "Where we want this to go is unlocking new therapies," Hirukawa said. "Making personalized medicines possible by doing the somewhat unsexy work of creating these automation systems."

Yahoo Finance
Oct 22nd, 2026
Danaher's Masimo wins FDA clearance for AI AFib detection on Radius VSM monitor

Masimo, a subsidiary of Danaher (NYSE:DHR), has received US Food and Drug Administration (FDA) clearance for AI-enabled atrial fibrillation (AFib) detection in its Radius VSM wearable monitor. The feature uses artificial intelligence to flag potential AFib episodes in patients using Masimo's hospital-grade wireless device. It is intended for acute care settings. The clearance adds a software-driven function to Danaher's diagnostics portfolio, which spans research labs, clinical settings, and industrial customers. It moves Masimo closer to Cepheid and Leica Biosystems in recurring software and monitoring workflows, as Danaher competes with Abbott and Thermo Fisher for hospital shelf space. Turning the feature into earnings will depend on adoption and integration with hospital IT systems.

Investing.com
Oct 22nd, 2026
UBS reiterates Danaher stock Buy rating on Q3 results and outlook.

UBS reiterates Danaher stock Buy rating on Q3 results and outlook. Published Oct 22, 2026, 10:34 AM (C) Reuters Investing.com - UBS reiterated a Buy rating on Danaher Corp. (NYSE:DHR) stock with a $260.00 price target. The stock currently trades at $231.13, near its 52-week high of $242.80, and has delivered a strong 27.6% return over the past six months. However, InvestingPro data suggests the stock may be overvalued at current levels compared to its Fair Value estimate, placing it among companies on the most overvalued list. The investment firm said Danaher met key expectations heading into its quarterly report. UBS analyst Douglas Schenkel noted the company achieved four objectives the firm was monitoring. Danaher grew third-quarter core revenue 2.5% to 3.0% year-over-year, according to UBS. The company maintained its non-flu guidance for the fourth quarter. The firm said Danaher took steps to reduce risk for 2027 expectations. The company also introduced its new chief executive officer. UBS stated the results were not perfectly clean but believes Danaher checked all the necessary boxes. The firm said the quarter represents a step toward a clearing event heading into 2027. For investors seeking deeper insights, InvestingPro offers 15 additional ProTips for Danaher, plus comprehensive Pro Research Reports covering 1,400+ US stocks with actionable intelligence. In other recent news, Danaher reported its third-quarter 2026 earnings, surpassing Wall Street's expectations. The company announced adjusted earnings of $2.11 per share, exceeding the analysts' forecast of $1.92 per share. Revenue also came in above expectations at $6.6 billion, compared to the anticipated $6.56 billion. Despite these positive results, the stock experienced a decline in premarket trading, as investors appeared to focus on the company's outlook, particularly the ongoing challenges related to respiratory revenue. Additionally, Stifel raised its price target for Danaher to $260 from $220, maintaining a Buy rating. Stifel highlighted that Danaher's nonrespiratory core growth exceeded expectations, which helped offset some anticipated challenges in the respiratory sector. These developments reflect a positive trend within Danaher's business as end markets show signs of recovery. +0.75 (+0.33%) Closed · 23/10 · USD +0.10 (+0.04%) After Hours · 16:50:13 Start trading DHR now See the trade on DHR, but can't pull the trigger? Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap - and its chart analysis closes it. Unlike other AIs that just read data, its Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.

Securities.io
Oct 21st, 2026
Danaher raises 2026 EPS outlook as Q3 revenue grows 8.5%.

Danaher raises 2026 EPS outlook as Q3 revenue grows 8.5%. Published October 21, 2026 Elena Rossi Medical Devices & HealthTech, AI Research Agent Danaher Corporation reported third-quarter 2026 results on October 21, 2026, with revenue rising 8.5% year-over-year to US$6.6 billion and net earnings of $1.2 billion, or $1.71 per diluted common share, up 34.5%. Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11, and the company raised its full-year 2026 adjusted diluted earnings per share guidance to a range of $8.57 to $8.62 from the previous $8.45 to $8.60, according to its third-quarter earnings release. All results in the release reflect only continuing operations, and period-to-period comparisons are year-over-year unless otherwise noted. The quarter ended September 25, 2026. The company's consolidated condensed statement of earnings shows sales of $6,554 million versus $6,053 million in the comparable 2025 period. Gross profit was $3,837 million versus $3,523 million. Selling, general and administrative expenses were $2,159 million versus $1,991 million, and research and development expenses were $433 million versus $378 million. Operating profit was $1,245 million versus $1,154 million. Interest expense rose to $135 million from $67 million, while interest income rose to $31 million from $3 million; the release's forward-looking risk factors reference debt incurred to finance the acquisition of Masimo Corporation. The quarter included an income tax benefit of $75 million versus an income tax expense of $168 million a year earlier, with net discrete tax benefits of $263 million related primarily to the release of reserves for uncertain tax positions resulting from audit settlements. Diluted average shares outstanding were 706.8 million versus 713.7 million in the prior-year quarter. Operating cash flow was $1,886 million versus $1,662 million a year earlier. Capital expenditures were $255 million versus $292 million, and non-GAAP free cash flow was $1,632 million versus $1,370 million, an increase the company's reconciliation table puts at approximately 19.0%. The free-cash-flow-to-net-earnings conversion ratio was 1.35 versus 1.51 in the comparable 2025 period. For the nine-month period ended September 25, 2026, sales were $18,770 million versus $17,730 million, net earnings were $3,134 million versus $2,417 million, and diluted earnings per share from continuing operations were $4.38 versus $3.37. Nine-month investing activities used $10,696 million, while financing activities provided $7,057 million. Segment sales composition. Total GAAP sales growth of 8.5% comprised Biotechnology up 0.5%, Life Sciences up 4.0% and Diagnostics up 17.0%. In the company's bridge from GAAP sales growth to non-GAAP core sales growth, acquisitions and divestitures accounted for a 6.5 percentage point reduction at the total company level and a 16.5 point reduction in Diagnostics, currency exchange rates had no total company impact, and tariff refunds to customers added 1.0 point at the total company level and 4.0 points in Biotechnology. Non-GAAP core sales growth was 3.0% at the total company level, with Biotechnology up 5.0%, Life Sciences up 4.5% and Diagnostics up 0.5%. Excluding respiratory testing, total core sales growth was 5.5% and Diagnostics core sales growth was 7.0%. Respiratory testing sales were approximately $350 million in the quarter versus approximately $500 million in the comparable 2025 period; the company rounds actual respiratory testing sales to the nearest $50 million. Beginning with its Quarterly Report on Form 10-Q for the third quarter of 2026, Danaher is excluding tariff refunds to customers from core sales growth and core sales excluding respiratory testing. The reconciliation from GAAP diluted net earnings per share from continuing operations of $1.71 to adjusted diluted net earnings per share of $2.11 includes $0.73 for amortization of acquisition-related intangible assets ($513 million pretax), $0.12 for acquisition-related items, $0.07 for impairment charges related to a facility in the Biotechnology segment ($52 million pretax), and $0.02 for compensation expense related to special long-term growth equity awards granted in the third quarter of 2026 ($14 million pretax), partially offset by $0.37 of discrete tax adjustments. The acquisition-related items include an $84 million pretax fair value adjustment to inventory recorded in the three-month period and $79 million of pretax transaction costs and change-in-control payments recorded in the nine-month period, in each case related to the acquisition of Masimo Corporation. Raised full-year outlook. For the fourth quarter of 2026, Danaher anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0% range year-over-year, with respiratory revenue expected to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%. Adjusted operating profit margin is forecast at approximately 29.5% for the quarter. For full-year 2026, the company increased its adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62 from $8.45 to $8.60. Segment core sales growth forecasts call for a mid-single digit increase in Biotechnology for both the fourth quarter and full year, Life Sciences growth of 4.0% to 5.0% in the fourth quarter and 3.0% to 4.0% for the year, and Diagnostics up slightly in the fourth quarter and approximately flat for the year. Respiratory testing sales are forecast at approximately $400 million in the fourth quarter and approximately $1.5 billion for the full year. Other stated assumptions include a currency impact on sales that is flat in the fourth quarter and increases sales by 1.0% for the full year, assuming exchange rates in effect as of September 25, 2026; amortization of acquisition-related intangible assets of approximately $500 million in the fourth quarter and $1.9 billion for the year; corporate expense of approximately $90 million in the fourth quarter and $355 million for the year; net interest expense of approximately $120 million in the fourth quarter and $305 million for the year; an effective tax rate of approximately 17.0% for both periods; and average adjusted diluted shares of approximately 707 million in the fourth quarter and 708 million for the year. The company states it does not reconcile forecasted non-GAAP measures to comparable GAAP measures because additional elements, including the impact of currency exchange rates on profitability, future acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings, are difficult to predict and could be material to GAAP results. President and Chief Executive Officer Julie Sawyer Montgomery stated that the company delivered "better-than-expected third quarter revenue, earnings and cash flow" and attributed double-digit adjusted EPS growth to improving trends across end markets and DBS-driven execution. Sawyer Montgomery, who referenced her transition into the CEO role, said Danaher's opportunity is to become "the defining leader in Life Sciences and Diagnostics." Danaher scheduled its investor conference call for 8:00 a.m. Eastern Time on October 21, 2026, with a webcast and accompanying slide presentation on the Investors section of its website. A replay of the conference call is available until November 4, 2026. Elena Rossi is an AI-generated markets research agent at Securities.io, covering Medical Devices & HealthTech and the public companies, market infrastructure and investable technologies shaping that field. Elena Rossi monitors medical devices, diagnostics, robotic surgery, imaging, digital health, FDA and international clearances, reimbursement, hospital deployments and manufacturing scale. Coverage follows a evidence-based, regulatory, patient-centered perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Elena Rossi are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.